How can value based care (VBC) better serve patients with kidney disease? Fresenius Medical Care North America (FMCNA) is leveraging its expertise to help design programs that balance the needs of patients, providers, and payors. Next-generation programs will most likely encompass a greater range of the disease, from chronic kidney disease (CKD) through end stage renal disease (ESRD) and kidney transplant. This longitudinal model can offer patients less fragmented and episodic care, a broader choice of treatments, and improved outcomes over the course of many years.
FMCNA became a pioneer in population health management in 2006 by extending a VBC contract to ESRD patients in an early Centers for Medicare and Medicaid Services (CMS) demonstration. FMCNA continues to lead in this space and is preparing for the next generation of VBC.
VBC programs continue to mature across the US healthcare landscape, driven by the insurance providers (payors) and the Center for Medicare and Medicaid Innovation (CMMI). One of the most successful of these programs, the Comprehensive ESRD Care (CEC) Model, commonly referred to as the ESRD Seamless Care Organization (ESCO) demonstration, is in its fourth year of a five-year program, with FMCNA operating nearly two-thirds of all ESCOs and caring for 80 percent of the beneficiaries. Because the ESCOs create financial savings and improve care, CMMI is developing the next generation VBC program modeled on the successful ESCO program to continue beyond 2020.
CMMI has indicated that the next generation renal program will likely encompass a greater range of the disease, from CKD through ESRD and kidney transplant. The US government's July 2019 announcement of the Advancing American Kidney Health initiative proposes to increase transplantation, home dialysis, and value based models including the introduction of voluntary and mandatory payment models beginning in January 2020. ESRD Treatment Choices (ETC) is a required model that adds new financial incentives to encourage dialysis at home and intends to enroll half of the nation's Medicare ESRD beneficiaries by randomly aligning beneficiaries using a specified geographic framework. To avoid penalizing ESRD providers with sicker patients, the model would risk adjust the home dialysis and transplant rates used for purposes of the performance payment adjustments. The administration is rolling out additional optional payment models through the CMMI.
Most renal patients never progress to dialysis, yet CKD is often overlooked in many VBC programs. Based on the US government's kidney-focused policy announcement, the successes of the ESCO program and public comment from CMMI and Health and Human Services (HHS) officials, FMCNA anticipates that most future renal VBC programs will encompass CKD care, in-center dialysis, home dialysis, transplant, and post-transplant care, removing many of the artificial boundaries that kidney disease and treatment modalities traditionally have been segmented into and managed independently. Beyond improvements in more holistic patient care, a more expansive VBC program solves one of the age-old dilemmas of health insurance: beneficiary turnover. It can be challenging for payors to invest in long-term outcomes when beneficiaries may leave the plan before such investments yield financial results. A broader kidney program covering a larger spectrum of the disease state creates a consistency with patients and gives organizations like FMCNA increased financial incentive to invest in patient care and improved health outcomes by providing population health management over the course of years. After all, kidney disease is a longitudinal chronic illness, with dialysis only one part of the care continuum.
Based on the National Health and Nutrition Examination Survey (NHANES) conducted by the United States Renal Data System (USRDS), 14.8 percent of patients surveyed have stages 1-5 and 6.9 percent have stages 3-5.1 There were 124,675 new dialysis patients in 2016.2 Less than half of 1 percent of adults are receiving dialysis, and fewer than 1 in 30 patients with CKD receive dialysis (Figure 1). Because there are many more patients with CKD than ESRD at any given point in time, an expanded VBC model that includes CKD would provide FMCNA the opportunity to improve outcomes for a greater number of people than just those with ESRD.
FIGURE 1 | Prevalence of chronic kidney disease
Delaying renal disease progression can save the payor—and, in some cases, the taxpayer via Medicare contributions—as much as $48,000 per year per patient.3
It is well established that starting dialysis is very difficult for patients socially, emotionally, and financially. Planning and preparation can not only help patients address and mitigate these challenges but also improve outcomes during this transition. FMCNA's Renal Care Coordinator (RCC) program engages patients by providing care coordination prior to the initiation of dialysis and during a patient's first 120 days receiving dialysis. In 2017, this intensive care coordination resulted in:4
Specific benefits of VBC programs that include the full renal disease spectrum are:
The next generation of VBC will have enhanced financial alignment. Payors seek to reduce the total cost of care and improve patient outcomes and lifestyles by having VBC programs designed to delay the progression to ESRD, facilitate more transplants, and encourage patients to seek home dialysis as their dialysis modality. The at-risk patient cohort must expand beyond ESRD to include pre- and post-ESRD to achieve these goals.
Stronger connections between payor (or CMS) and the participants (FMCNA and partners) with more financial transparency and increased flexibility will deliver innovative care by eliminating barriers to renal care inherent in a fee-for-service delivery system.
Some specifics of the next generation of VBC programs will hopefully include:
Further improvements to VBC programs will likely include payor- supported enhanced benefits and, within CMMI demonstrations, the use of waivers, deviating from the established limitation of fee-for-service in Medicare. These will include:
Having a VBC model that includes CKD, dialysis, and post-transplant care allows for patient participation over a greater duration of their renal disease state. This results in improved care continuity, slower disease progression, better ESRD care choices, higher home dialysis modalities selection, more transplant options, better post-transplant care, and a reduction in the total cost of care. The next generation of renal value based programs will include more patients, participating for a longer period, and they will benefit from longitudinal care integration. FMCNA is poised to help design and deliver the next generation of programs to benefit patients, payors, and providers alike.
ANDREW ARONSON, MD, FACEP
Senior Vice President, Chief Clinical Operations Officer, Fresenius Health Partners
Andy Aronson oversees the clinical aspects of ESRD Seamless Care Organizations and the commercial ESRD programs. He is a Board-Certified Emergency Physician, a fellow of the American College of Emergency Physicians, and on the editorial board of the Journal of Population Health Management. He completed medical school at Drexel University College of Medicine and emergency medicine residency at Brigham and Women's Hospital and Massachusetts General Hospital.